Fermer le menu


Member of Lyonbiopole


DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial dark matter".

By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance.

The new therapies discovered and developed by DEINOVE target superbugs -microbes that have become resistant to one or more antimicrobials - that cause life-threatening infections, which are now spreading at high speed.

This breakthrough approach gave rise to one of the world’s first specialized micro-biotechnology platforms and a unique collection of 10,000+ rare strains and thousands of bacterial extracts.

Today, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the world’s first emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.


Strategic application domain: Human Medicine

Application market: Infectious Diseases

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Cell Therapy - Stem cells - Cell Biology - Biobanking, Molecular Biology & Nucleic acid, Screening methods or services

Created on sept. 15th, 2006 - 54 employees



CAP SIGMA, ZAC Euromédecine II, 1682 rue de la Valsière 34790 Grabels



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.